Background: Primary central nervous system lymphoma (PCNSL) is a rare central nervous system tumor, especially in the pediatric population. There are fewer than 20 described cases of pediatric primary central nervous system anaplastic large cell lymphoma. The child described in our case report demonstrated a dramatic evolution of this tumor in the first 4 weeks on serial imaging. Methods: Serial MRI imaging was performed followed by biopsy and chemotherapy. Results: Initial imaging revealed a T2 hyperintense lesion in the frontal lobe with abnormally enhancing sulci and minimal surrounding edema and diffusion restriction. Serial imaging revealed progressive increase in the degree of gadolinium enhancement, and the hyperintense T2 edema progressed markedly to exert mass effect. The lesion itself grew marginally. Biopsy revealed an anaplastic large cell lymphoma, only described in 14 previous pediatric patient case reports. The patient was successfully treated with chemotherapy and autologous stem cell transplant. Conclusions: Our case demonstrates the rapidity with which a PCNSL lesion can develop, and the evolution of the imaging characteristics prior to definitive diagnosis and treatment. Serial imaging by MRI may help differentiate the behavior of a PCNSL from other imitating lesions.

Keywords:
Primary central nervous system lymphoma, Anaplastic large cell lymphoma, Magnetic resonance imaging
1.
Hoffman S, Propp JM, McCarthy BJ: Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol 2006;8:27-37.
2.
Kadan-Lottick NS, Skluzacek MC, Gurney JG: Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002;95:193-202.
3.
Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, et al: Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 2000;92:261-266.
4.
Coulon A, Lafitte F, Hoang-Xuan K, Martin-Duverneuil N, Mokhtari K, Blustajn J, et al: Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol 2001;12:329-340.
5.
Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA: A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA Neurol 2013;70:311-319.
6.
Küker W, Möhrle S, Mader I, Schöning M, Nägele T: MRI for the management of neonatal cerebral infarctions: importance of timing. Childs Nerv Syst 2004;20:742-748.
7.
Bühring U, Herrlinger U, Krings T, Thiex R, Weller M, Küker W: MRI features of primary central nervous system lymphomas at presentation. Neurology 2001;57:393-396.
8.
Küker W, Nägele T, Korfel A, Heckl S, Thiel E, Bamberg M, et al: Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 2005;72:169-177.
9.
Korfel A, Schlegel U: Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 2013;9:317-327.
10.
Herrlinger U, Schabet M, Bitzer M, Petersen D, et al: Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 1999;43:219-226.
11.
Sobrido Sampedro C, Corroto JD, et al: Findings at presentation in primary CNS diffuse large B-cell lymphoma of the brain: a comparison of immunocompetent and immunodeficient patients. J Biomed Graphics Computing 2013;3:59-69.
12.
Haldorsen IS, Espeland A, Larsson EM: Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 2011;32:984-992.
13.
Zhang D, Hu L-B, Henning TD, Ravarani EM, Zou L-G, Feng X-Y, et al: MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol 2010;11:269-277.
14.
Buxton N, Punt J, Hewitt M: Primary Ki-1- positive T-cell lymphoma of the brain in a child. Pediatr Neurosurg 1998;29:250-252.
15.
Havlioglu N, Manepalli A, Galindo L, Sotelo-Avila C, Grosso L: Primary Ki-1 (anaplastic large cell) lymphoma of the brain and spinal cord. Am J Clin Pathol 1995;103:496-499.
16.
Merlin E, Chabrier S, Verkarre V, Cramer E, Delabesse E, Stéphan J-L: Primary leptomeningeal ALK+ lymphoma in a 13-year-old child. J Pediatr Hematol Oncol 2008;30:963-967.
17.
Abdulkader I, Cameselle-Teijeiro J, Fraga M, Rodriguez-Núnez A, Allut AG, Forteza J: Primary anaplastic large cell lymphoma of the central nervous system. Hum Pathol 1999;30:978-981.
18.
George DH, Scheithauer BW, Aker FV, Kurtin PJ, Burger PC, Cameselle-Teijeiro J, et al: Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. Am J Surg Pathol 2003;27:487-493.
19.
Ozkaynak MF: Favorable outcome of primary CNS anaplastic large cell lymphoma in an immunocompetent patient. J Pediatr Hematol Oncol 2009;31:128-130.
20.
Rupani A, Modi C, Desai S, Rege J: Primary anaplastic large cell lymphoma of central nervous system - a case report. J Postgrad Med 2005;51:326-327.
21.
Bergmann M, Edel G: Primary intracerebral non-Hodgkin's lymphoma. Pathologe 1991;12:246-253.
22.
Abla O, Sandlund JT, Sung L, Brock P, Corbett R, Kirov I, et al: A case series of pediatric primary central nervous system lymphoma: favorable outcome without cranial irradiation. Pediatr Blood Cancer 2006;47:880-885.
23.
Karikari IO, Thomas KK, Lagoo A, Cummings TJ, George TM: Primary cerebral ALK-1-positive anaplastic large cell lymphoma in a child. Case report and literature review. Pediatr Neurosurg 2007;43:516-521.
24.
Shah AC, Kelly DR, Nabors LB, Oakes WJ, Hilliard LM, Reddy AT: Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients. Pediatr Blood Cancer 2010;55:1227-1230.
25.
Manenti G, Di Giuliano F, Bindi A, Liberto V, Funel V, Garaci FG, et al: A case of primary T-cell central nervous system lymphoma: MR imaging and MR spectroscopy assessment. Case Rep Radiol 2013;2013:916348.
26.
Tang YZ, Booth TC, Bhogal P, Malhotra A, Wilhelm T: Imaging of primary central nervous system lymphoma. Clin Radiol 2011;66:768-777.
27.
Yap KK, Sutherland T, Liew E, Tartaglia CJ, Pang M, Trost N: Magnetic resonance features of primary central nervous system lymphoma in the immunocompetent patient: a pictorial essay. J Med Imaging Radiat Oncol 2012;56:179-186.
28.
Schwingel R, Reis F, Zanardi VA, Queiroz LS, França MC: Central nervous system lymphoma: magnetic resonance imaging features at presentation. Arq Neuropsiquiatr 2012;70:97-101.
29.
Haldorsen IS, Kråkenes J, Krossnes BK, Mella O, Espeland A: CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989-2003. AJNR Am J Neuroradiol 2009;30:744-751.
30.
Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW: Patterns of contrast enhancement in the brain and meninges. Radiographics 2007;27:525-551.
31.
Gliemroth J, Kehler U, Gaebel C, Arnold H, Missler U: Neuroradiological findings in primary cerebral lymphomas of non-AIDS patients. Clin Neurol Neurosurg 2003;105:78-86.
32.
Erdag N, Bhorade RM, Alberico RA, Yousuf N, Patel MR: Primary lymphoma of the central nervous system. AJR Am J Roentgenol 2001;176:1319-1326.
33.
Koeller KK, Smirniotopoulos JG, Jones RV: Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics 1997;17:1497-1526.
34.
Johnson BA, Fram EK, Johnson PC, Jacobowitz R: The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol 1997;18:563-572.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.